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Captopril-associated agranulocytosis
A .report of 3 cases
P.!. PILLANS, A. KOOPOWITZ
Summary
Three cases of captopril-associated neutropenia are des-
cribed, which illustrate the clinical presentation, variable pre-
disposing factors and outcome of this rare but potentially
serious adverse event. Particular risk factors of renal failure
and collagen vascular disease were present in only 1 patient,
while a second patient had reversible mild renal impairment.
The doses of captopril used ranged from 25 mg to 50 mg 3
times a day. Two patients recovered after withdrawal of the
drug but the third died of septicaemia. Captopril-associated
agranulocytosis is reviewed.
S Air Med J 1991; 79: 399-400.
Case reports
Case 1
A 56-year-old woman with longstanding hypertension suf-
fered a myocardial infarction in May 1989. In Noven:!ber 1989
she was admitted to hospital with pulmonary oedema and was
subsequently started on captopril, the dosage being increased
to 50 mg 3 times a day. Previous medication, namely amiloride
5 mg plus hydrochlorothiazide 50 mg once daily and aspirin
150 mg daily was continued. Three weeks later she was again
admitted to hospital with a temperature of 38,3°C and a septic
lesion on the right little fmger with lymphangitis extending up
the forearm. Although there was clinical evidence of cardio-
megaly she was not in cardiac failure. A full blood count
revealed a haemoglobin level of 13,4 gldl and platelet count of
291 X 109/1. The white cell count was reduced at 3,4 X 109/1
with 0% neutrophils, 51% lymphocytes, 44% monocytes, 2%
eosinophils and 3% basophils. Biochemical investigations gave
normal results except for a mildly elevated serum urea value of
10,5 mmoVl (normal 1,7 - 6,7 mmoVl) and creatinine of 145
j.Lmol/l (normal 75 - 115 j.LmoVI), both of which had returned
to normal by the 4th day in hospital. Urine examination, three
blood cultures, VDRL test and lupus profIle were all negative.
Chest radiography was non-contributory except for left ventri-
cular cardiomegaly. Captopril was discontinued and the infec-
tion treated with cloxacillin and clindamycin. On the 2nd day
in hospital the white cell count was 2,67 X 109/1 with 4%
neutrophils but the following day it had risen to 4,0 X 109/1
with 35% neutrophils and on the 6th day to 6,71 X 109/1 with .
53% neutrophils. The temperature senled and the patient
made an uneventful recovery. The white cell count 34 days
after admission to hospital was 6,47 X 109/1 with 58% neutro-
phils. Rechallenge was not attempted.
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Case 2
A 31-year-old woman with systemic lupus erythematosus,
membranous nephropathy, chronic renal failure and hyper-
tension was on medication that included prednisone 40 mg
daily, nifedipine 10 mg 3 times a day, furosemide I g daily,
metolazone 5 mg daily, and atenolol 100 mg daily. On 4
October 1989 enalapril was started at 2,5 mg daily and the
dose was subsequently increased to 5 mg daily with no
untoward effect. On 21 November 1989 the angiotensin-
converting enzyme (ACE) inhibitor was changed to captopril,
reaching a maximum dose of 50 mg 3 times a day. Other
medication was continued. On 4 December 1989 at a routine
follow-up examination the haemoglobin value was 7,4 g/dl,
the white cell count 11,3 X 109/1 with 95% neutrophils, in
keeping with high-dose corticosteroids, and platelets 406 X
109/1.
On II January 1990 the patient was admitted to hospital
with a 2-week history of generalised erythematous maculo-
papular rash, intermittent fever, myalgia and arthralgia. On
examination she was pale, the temperature was 37,8°C, an
infected right thumb was noted and there was ascites con-
sidered to be secondary to the nephrotic syndrome.
Chest radiography showed bilateral pleural effusions with
consolidation of the apical segment of the right lower lobe.
Blood cultures were negative, sputum and urine revealed
mixed organisms and there was no growth from the ascitic
fluid. A swab from the infected right thumb grew Scaphylo-
coccus aureus. A full blood count revealed a normochromic
normocytic anaemia with a haemoglobin value of 8 g/dl and a
platelet count of 379 X 109/1. The white cell count was
markedly decreased at 0,32 X 109/1 with 5% neutrophils, 66%
Iymphocytes, 10% monocytes, 4% basophils and IS large un-
stained cells. Biochemical investigations were remarkable for
elevated serum urea of 49,6 mmoVI and creatinine of 394
mmoVI, decreased serum albumin of 25 mmol/I (normal
35 - 50 mmoVI), elevated inorganic phosphate of 3,2 mmoVI
(normal 0,8 - 1,4 mmoVI) and increased cholesterol of 7,3
mmoVI (normal 3,1 - 7,1 mmoVI) in keeping with chronic
renal failure and the nephrotic syndrome. Captopril was
stopped, but other medicines continued, and intravenous
penicillin was started, which was changed the following day 10
intravenous ceftriaxone. The pyrexia settled and the patient's
symptoms improved. Fourteen days later, on 25 January 1990,
the white cell count was 1,35 X 109/1 with 37% neutrophils, on
30 January it was 3,84 X 109/1 and on 17 April 1990 it was
6,12 X 109/1 with 79% neutrophils. Rechallenge with captopril
was not attempted.
Case 3
A 51-year-old woman with no illness of note except hyper-
tension was treated with captopril 25 mg 3 times a day for 4
months. She presented to hospital with a sore throat and a
white cell count of 0,68 X 109/1. The neutrophil count was
0,1 X 109/1. A previous white cell count was normal at 11,2 X
109/1 as were the serum urea of 5,7 mmoVI and serum
creatinine of 95 mmoVI. The patient developed septicaemia
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and died despite treatment with penicillin, cefotaxime, amika-
cin, imipenim and metronidazole.
Discussion
The ACE inhibitors are gammg wider acceptance in the
treatment of cardiac failure and hypertension. Although adverse
effects, such as hypotension, rash, proteinurea, taste distur-
bance and cough are well known, it is important that pre-
scribers are aware of the potentially serious, albeit rare, haema-
tological events.
The neutropenia and agranulocytosis associated with cap-
topril typically occur within 3 - 12 weeks of the start of
treatment. Particular risk factors are renal impairment and
collagen vascular disease, such as lupus erythematosus or
scleroderma. I-3 In patients with normal renal function and no
collagen vascular disease, the overall incidence of neutropenia
has been quoted as 0,02%, whereas in patients with both
collagen vascular disease and renal failure the incidence is
much higher (3,7 - 7,2%).3,4 Patient 2, who had lupus erythe-
matosus and chronic renal failure, is a typical example of a
patient at increased risk. Other reports of neutropenia and
agranulocytosis have been in patients on very large doses of
captopril - up to 600 mg daily5-8 - although agranulocytosis
has been described in patients on 12,5 - 100 mg captopril
daily.9 Our third patient, who was on maximal, although not
an excessive, dose of captopril illustrates the development of
agranulocytosis in the absence of predisposing diseases.
Following discontinuation of captopril the neutrophil count
usually returns to normal within 3 weeks and this has been
reported to occur as early as 2 - 3 days after stopping
medication,9 which is in keeping with our first case. Some
patients have been rechallenged with captopril after recovery,
often with reduced dosages, and whereas some have experienced
recurrence, most have not, possibly suggesting a dose-response
phenomenon in those without recurrence. 2 Although septi-
caemia may be associated with neutropenia the negative blood
cultures in the first case and rapid recovery are in keeping
wi~ capropril-related agranulocytosis. In the third case septi-
caemia cannot. be positively excluded as the cause for the
profound leukopenia and neutropenia.
The renin-angiotensin system appears to contribute substan-
tially to maintenance of glomerular filtration in patients with
congestive heart failure in whom renal perfusion is com-
promised, and renal function may deteriorate during therapy
with an ACE inhibitor. I This probably occurred in our first
case, predisposing to accumulation of captopril, which is pri-
marily eliminated by the kidney. Serum creatinine levels
returned to normal after captopril was discontinued.
Captopril-associated neutropenia is reversible, but death has
occurred in up to 13% of patients who have developed neutro-
penia, although most fatalities have been reported in patients
with associated serious collagen vascular disease, renal failure
or heart failure.I,IO,11 Our third case, however, illustrates that
septicaemia complicating neutropenia may be fatal in an other-
wise well patient.
There has been considerable discussion about whether the
side-effect of neutropenia is drug-specific for captopril or
class-specific for the ACE inhibitors. It is hypothesised that
the sulphydryl group in captopril as in penicillamine contri-
butes to the development of this adverse effect. Reports from
users of captopril and enalapril in the UK, which show a
higher incidence of captopril-associated granulocytopenia,
pancytopenia or aplastic anaemia (27 of 81 000 patient.s) com-
pared with only 1 out of 31 000 patients on enalapril, favour a
captopril-specific effect. 4 However, experience with other ACE
inhibitors is limited in patients with concomitant collagen
vascular disease and renal failure.
Except in patients with collagen vascular disease and renal
failure, this rare complication is not an indication for routine
full blood counts in patients on ACE inhibitors. However, if a
patient develops a sore throat or other signs of infection a
white· cell count, including a differential count, should be
performed.
We thank Professor R. van Zyl-Smit for permission to present
the second case.
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